Loading...
Market
What will be Marea Therapeutics' next milestone announcement by December 18, 2024?
5
Resolution / Starting Odds
Initiate clinical trial • 25%
Secure additional funding • 25%
Enter partnership • 25%
Other • 25%
Public announcements or press releases from Marea Therapeutics
Story
Third Rock-backed Marea Therapeutics Launches with $190M to Tackle Cardiometabolic Diseases Targeting ANGPTL4
Jun 18, 2024, 11:49 AM
Marea Therapeutics has launched with $190 million in funding to develop new treatments for cardiometabolic diseases. The biotech company, which focuses on leveraging large-scale human genetics and adipose biology, aims to address the lingering issue of high cholesterol and cardiovascular disease. Founded by Ethan Weiss and led by CEO Josh Lehrer, Marea targets the ANGPTL4 gene, which has been linked to cardiometabolic disease but has not attracted much interest from the pharmaceutical industry due to safety concerns. The Third Rock-backed, 10-person startup plans to use its funding to pioneer the next frontier of cardiometabolic medicines and improve patient outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Another cancer therapy • 25%
A non-cancer therapy • 25%
No new approvals • 25%
Other • 25%
Phase II trial results • 25%
Phase III trial initiation • 25%
New partnership announcement • 25%
Other • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%
Initiation of Phase 1 clinical trials • 25%
Publication of preclinical study results • 25%
Securing additional funding • 25%
Partnership with a major pharmaceutical company • 25%
Phase III trial initiation • 25%
FDA accelerated approval • 25%
New interim data release • 25%
Other milestone • 25%
Yes • 50%
No • 50%
Phase 2 Completion • 25%
Partnership/Acquisition • 25%
FDA Approval • 25%
Other • 25%
Announces new clinical trial • 25%
Announces new partnership • 25%
Announces new funding • 25%
No significant announcements • 25%